Takeaway: Regulatory Agencies Split on New Alzheimer’s Drugs as Hope Meets Uncertainty

GMJ
By
Prof. Giorgi Pkhakadze
0 Min Read
Regulatory agencies reviewing Alzheimer's disease treatment approvals with conflicting decisions
Regulatory agencies worldwide are delivering conflicting assessments of novel Alzheimer's treatments, creating uncertainty for millions of patients. The Lancet examines divergent approval pathways and their implications for global access. — Photo: SHVETS production / Pexels
1 min read|35 words

3 key insights on Alzheimer's drug regulation: 1️⃣ Major agencies reach different conclusions on same treatments 2️⃣ New drugs show 20-30% slowing but clinical significance debated 3️⃣ Cost-effectiveness concerns shape access decisions

Read the full article on GMJ Newsroom →

Was this article helpful?

Related reference
Share This Article
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Rare Lymphatic-Urinary Fistula Causes Milky Urine in NEJM Case Report

A rare case of chyluria caused by a lymphatic-urinary fistula demonstrates how…

Gene Therapy Shows Promise for Inherited Cholesterol Disorder in First-in-Human Trial

First-in-human gene therapy trial shows preliminary safety and efficacy for treating homozygous…

Teen Drug Use and Binge Drinking Linked to Severe Mental Health Crisis

UCLA research reveals dangerous links between teen substance use and mental health…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like